xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts October 19, 2009 : BMRC, FGXI, VITA, CWBC, EGOV and IDRA

Xtremepicks.com Alerts include Bank of Marin Bancorp (NASDAQ: BMRC), FGX International Holdings Limited (NASDAQ: FGXI), Orthovita, Inc. (NASDAQ: VITA), Community West Bancshares (NASDAQ: CWBC), NIC Inc. (NASDAQ: EGOV) and Idera Pharmaceuticals, Inc. (Nasdaq: IDRA)

Bank of Marin Bancorp (NASDAQ:BMRC) trading at $32.27 per share on trading volume of 1,791 shares.

In a press release out on October 19, Bank of Marin Bancorp Reports Record Third Quarter Earnings Increase of 34%

Maintains Healthy Credit Quality and Enhances Capital Strength

NOVATO, Calif., Oct 19, 2009 -- Bank of Marin Bancorp ("Bancorp") (NASDAQ:BMRC) announced 2009 third-quarter earnings of $3.6 million, up $906 thousand, or 33.6%, from the same period a year ago, and up $468 thousand, or 14.9% from the second quarter of 2009. Diluted earnings per share were $0.68 in the third quarter of 2009, up sixteen cents, or 30.8% from the third quarter of 2008, and up eight cents, or 13.3% from the second quarter of 2009.

About Bank of Marin Bancorp

Bank of Marin Bancorp's assets currently exceed $1 billion. Bank of Marin, as the sole subsidiary of Bancorp, operates thirteen branch offices in California and a commercial loan production office in San Francisco. The Bank's Administrative offices are located in Novato, California and its Wealth Management Services are located in Greenbrae, Novato and Petaluma, California. Bank of Marin is included in the Russell 2000 Small-Cap Index, is recognized as one of thirty top performing small-cap banks by Sandler O'Neill + Partners, and has received the highest five star rating from Bauer Financial for 41 consecutive quarters. (www.bauerfinancial.com). Bank of Marin has been recognized as one of the "Best Places to Work in the Bay Area" and one of the "Top Corporate Philanthropists" by the San Francisco Business Times.

FGX International Holdings Limited (NASDAQ: FGXI) trading at $14.56 per share on trading volume of 923 shares.

In a press release out on October 19, FGX International Announces Third Quarter 2009 Earnings Call

SMITHFIELD, R.I., Oct 19, 2009 -- FGX International Holdings Limited (NASDAQ: FGXI) announced today that it expects to release third quarter 2009 financial results after the market closes on Wednesday, November 4, 2009. The Company will hold a conference call on Thursday, November 5, 2009 at 8:30 AM ET, hosted by Alec Taylor, Chief Executive Officer, Anthony DiPaola, Chief Financial Officer and Jack Flynn, President to discuss its latest financial results.

About FGX International

FGX International Holdings Limited is a leading designer and marketer of non-prescription reading glasses and sunglasses with a portfolio of established, highly recognized eyewear brands including Foster Grant(R), Magnivision(R), Angel (TM) , Gargoyles(R), Anarchy(R), SolarShield(R) and PolarEyes(R). FGXI also holds licenses for brands such as Ironman, Levi Strauss, Field & Stream, Body Glove and C9 by Champion. Based in Smithfield, Rhode Island, FGXI has approximately 375 full time employees. Additional offices are located in San Luis Obispo, CA; Toronto, Canada; Stoke-on-Trent, England; Mexico City, Mexico; and Shenzhen, China.

Orthovita, Inc. (NASDAQ: VITA) trading at $4.32 per share on trading volume of 71,994 shares.

In a press release out on October 19, Orthovita Schedules Third Quarter 2009 Financial Results Conference Call

MALVERN, Pa., Oct 19, 2009 -- Orthovita, Inc. (NASDAQ: VITA), a leading orthobiologics and biosurgery company, will hold a conference call on Thursday, November 5, 2009, at 8:30 a.m. Eastern Time, to review and discuss its financial results for the third quarter 2009. Antony Koblish, President and Chief Executive Officer, and Nancy C. Broadbent, Senior Vice President and Chief Financial Officer of Orthovita, will host the call.

About the Company

Orthovita is an orthobiologics and biosurgery company that develops and markets novel medical devices. Our orthobiologics platform offers products for the fusion, regeneration and fixation of human bone. Our biosurgery platform offers products for controlling intra-operative bleeding, also known as hemostasis. Our current fusion and regeneration products are based on our proprietary Vitoss(TM) Bone Graft Substitute technology and address the non-structural bone graft market with synthetic, bioactive alternatives to patient- and cadaver-derived bone tissue. Cortoss(TM) Bone Augmentation Material, an injectable, polymer composite that mimics the structural characteristics of human bone, provides the basis for our fixation portfolio. Cortoss received U.S. regulatory clearance in June 2009 for use in vertebral augmentation. Our hemostasis portfolio includes Vitagel(TM) Surgical Hemostat, a unique, collagen-based matrix that controls bleeding and facilitates healing, and Vitasure(TM) Absorbable Hemostat, a plant-based product that can be deployed quickly throughout surgery.

Community West Bancshares (NASDAQ:CWBC) trading at $2.56 per share on trading volume of 1,900 shares.

In a press release out on October 19, Community West Bancshares Reports Q3 Results

GOLETA, Calif., Oct 19, 2009 -- Community West Bancshares (Company) (NASDAQ:CWBC), parent company of Community West Bank, today reported net income of $69,000 for the quarter ended September 30, 2009 (2009 Q3), compared to net income of $675,000 for the quarter ended September 30, 2008 (2008 Q3). For the nine months ended September 30, 2009, the Company reported a net loss of $(5,860,000) compared to net income of $1,420,000 for the nine months ended September 30, 2008. Net income per diluted share available to common shareholders, after the preferred stock dividends, was $(.03) for 2009 Q3 compared to $.11 for 2008 Q3.

Community West Bancshares is a financial services company with headquarters in Goleta, California. The Company is the holding company for Community West Bank, which has five full-service California branch banking offices, in Goleta, Ventura, Santa Maria, Santa Barbara and Westlake Village. The principal business activities of the Company are Relationship banking, Mortgage lending and SBA lending.

NIC Inc. (NASDAQ: EGOV) trading at $8.89 per share on trading volume of 22,110 shares.

In a press release out on October 19, Federal Department of Transportation Awards NIC Technologies with Contract for National Motor Carrier Pre-Employment Screening System

OLATHE, Kan., Oct 19, 2009 -- The U.S. Department of Transportation, Federal Motor Carrier Safety Administration (FMCSA), has awarded NIC Technologies, LLC, the contract for a National Motor Carrier Pre-Employment Screening System. NIC Technologies is part of the NIC Inc. (NASDAQ: EGOV) family of companies. The contract has an initial one-year term, with four, single-year renewals.

About NIC

NIC Inc. (NASDAQ: EGOV) is the nation's leading provider of official government portals, online services, and secure payment processing solutions. The company's innovative eGovernment services help reduce costs and increase efficiencies for government agencies, citizens, and businesses across the country. The NIC family of companies provides eGovernment solutions for more than 3,000 federal, state, and local agencies that serve 97 million people in the United States. Additional information is available at http://www.nicusa.com.

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) trading at $7.79 per share on trading volume of 1,475 shares.

In a press release out on October 19, Idera Pharmaceuticals Presents Preclinical Data at ACR/ARHP 2009 Annual Meeting on IMO-3100, a Toll-Like Receptor Antagonist, in Combination with Enbrel(R) in Arthritis Model

CAMBRIDGE, Mass., Oct 19, 2009 -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the presentation of preclinical data from studies of IMO-3100 in combination with Enbrel (etanercept) in a mouse model of arthritis. IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, is a lead drug candidate that Idera is developing for potential applications in autoimmune diseases. Enbrel is an inhibitor of TNF-alpha currently used for the treatment of rheumatoid arthritis. The presentation is being made at the 2009 Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) being held in Philadelphia, PA, October 17-21.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors (TLRs), which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for our internal development programs and our partnered programs, and generates opportunities for additional collaborative alliances. For more information, visit www.iderapharma.com.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: arthritis, bank, banking, business, california, canada, cancer, carrier, ceo, china, college, commercial, community, conference, contract, corporate, dna, earnings, email, e-mail, employment, england, family, federal, financial results, financial services, government, health, index, investment, investment opinion, kansas, licenses, local, market, medical, mexico, mortgage, nasdaq, online, pennsylvania, pharmaceuticals, plant, president, products, profit, respiratory, rhode island, small cap, surgery, technology, toronto, vaccine, web